Cart
sales@molnova.com
Zotizalkib
CAS No. 2648641-36-3
Zotizalkib( —— )
Catalog No. M37625 CAS No. 2648641-36-3
Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 1095 | Get Quote |
|
| 50MG | 1426 | Get Quote |
|
| 100MG | 2015 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZotizalkib
-
NoteResearch use only, not for human use.
-
Brief DescriptionZotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.
-
DescriptionZotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities.
-
In Vitro——
-
In VivoAnimal Model:Female SCID/beige mice (5-8 weeks old) bearing Ba/F3 cells Dosage:2 mg/kg, 5 mg/kg, and 10 mg/kg Administration:p.o.; twice a day; for 2 weeks Result:Caused complete tumor regression in ALK mutation-dependent xenograft models.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2648641-36-3
-
Formula Weight447.41
-
Molecular FormulaC21H20F3N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (139.69 mM; Ultrasonic (<80°C)
-
SMILESC(F)(F)[C@H]1N2C=3C(=CN4C(N3)=C(C=N4)C(=O)NC(C)(C)COC=5C(C2)=CC(F)=CC5)OC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brion W Murray, et al. TPX-0131, a Potent CNS-Penetrant, Next-Generation Inhibitor of Wild-Type ALK and ALK-Resistant Mutations. Mol Cancer Ther. 2021 Jun 22;molcanther.0221.2021.?
molnova catalog
related products
-
CEP-28122 mesylate
A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.
-
Tyrphostin AG 879
Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.
-
Iruplinalkib
Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
